KALA — Kala Pharmaceuticals Inc

Kala Pharmaceuticals Inc (KALA) is a biotechnology company listed on NASDAQ. It is led by Avi Minkowitz, based in 1167 Massachusetts Avenue, Arlington, MA, United States, 02476, with about 6 employees. KALA BIO, Inc., a biopharmaceutical company, engages in the development of an on-premises artificial intelligence (AI) infrastructure platform for biotechnology research applications in the United States. The company develops Researgency, an agentic AI research platform for private enterprise AI deployment. Its platform intends to utilize the KPI-012 clinical development dataset as a proof-of-concept validation environment, as well as the mesenchymal stem cell secretome (MSC-S) and persistent corneal epithelial defects (PCED) research for agentic workflows on trial data. The company serves biotechnology and pharmaceutical companies. The company was formerly known as Kala Pharmaceuticals, Inc. and changed its name to KALA BIO, Inc. in August 2023. KALA BIO, Inc. was incorporated in 2009 and is headquartered in Arlington, Massachusetts.

Net income was -$1.6M. KALA currently screens at market cap $54.3M.

Use this KALA page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the KALA quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the KALA SEC filings page. Lician reads the product cache first so this HTML stays unique to Kala Pharmaceuticals Inc even when a live quote feed is slow.